Search

A recent study conducted by Mayo Clinic explored the association between the risk of Alzheimer's disease and the use of Angiotensin II receptor blockers (ARBs) in individuals with hypertension. The study found that ARB users had a lower risk of developing Alzheimer's disease compared to other antihypertensive medication users. The research suggests that ARBs may be more effective in reducing the hazard of Alzheimer's disease among patients with hypertension, particularly those with ARBs that can cross the blood-brain barrier. The study highlights the potential of ARBs as a preventive measure for Alzheimer's disease and related dementias. [Extracted from the article]

A recent study from Tulane University highlights a case of a 46-year-old woman with a pheochromocytoma, a rare tumor that produces hormones. The patient presented with elevated catecholamines, thyroid nodules, and high calcitonin levels, prompting concern for medullary thyroid carcinoma. After undergoing surgery to remove the adrenal mass and thyroid nodule, the patient's calcitonin levels returned to normal, confirming the diagnosis of pheochromocytoma. The research emphasizes the importance of investigating high calcitonin levels in patients with pheochromocytoma, as it may not always be related to the thyroid. [Extracted from the article]

A recent study conducted by researchers from Mayo Clinic in Rochester, Minnesota, explored the use of Ga-68 Ga-GRPr PET imaging for detecting primary prostate cancer lesions. The study analyzed data from 9 studies involving 291 patients and 350 intra-prostatic lesions. The results showed that Ga-68 Ga-GRPr PET imaging had a high detection rate for primary prostate cancer, comparable to multiparametric magnetic resonance imaging (mpMRI). The researchers concluded that further research is needed to determine the effectiveness of Ga-68 Ga-GRPr PET imaging in providing additional imaging data and guiding therapeutic decisions. [Extracted from the article]

A recent report from Tulane University in New Orleans, Louisiana, discusses the challenges of using mu-opioid receptor agonists for chronic pain management due to their significant side effects and the development of tolerance. The researchers investigated the effects of a specific mu-opioid receptor agonist called ZH853 on neuropathic pain in rats. They found that chronic ZH853 treatment led to decreased tolerance and reduced glial activation compared to chronic morphine treatment. This study suggests that ZH853 may be a more effective and potentially safer alternative for managing neuropathic pain. [Extracted from the article]

Researchers at the University of Laval in Quebec City, Canada have conducted a study on the impact of angiotensin receptor blockers (ARBs) on aortic stenosis (AS), a condition characterized by the narrowing of the aortic valve. The study found that women with AS who took ARBs had significantly lower levels of valvular fibrosis compared to women who did not take ARBs. This effect was not observed in men. The researchers concluded that ARBs may have a larger therapeutic role in women with AS. [Extracted from the article]

Researchers at the National Autonomous University of Mexico (UNAM) have conducted a study on the neural activity that drives social interaction. They have identified direct projections from the hypothalamic supraoptic nucleus to the cortico-amygdalar nucleus of the lateral olfactory tract (NLOT), which is involved in promoting social behavior. The study found that water deprivation increased sociability in rats, and microinjections of arginine vasopressin (AVP) into the NLOT produced similar changes in sociability. The research suggests that during challenges to water homeostasis, a cooperative circuit involving glutamatergic and multi-peptidergic pathways promotes social behavior. [Extracted from the article]

A systematic review conducted by Mayo Clinic researchers compared the use of vasopressin-receptor agonists with norepinephrine for treating hypotension in adults undergoing surgery with general anesthesia. The review included 13 randomized controlled trials (RCTs) involving a total of 719 participants. The findings showed that there was no significant difference in all-cause mortality between the two treatments. However, among patients with vasoplegic shock after cardiac surgery, vasopressin was associated with lower intensive care unit and hospital lengths of stay, as well as fewer cases of acute kidney injury and atrial fibrillation compared to norepinephrine. The researchers concluded that more high-quality trials are needed to determine the overall treatment effects, especially among noncardiac surgical patients and those treated with vasopressin analogs. [Extracted from the article]

A study conducted by the University of Texas Southwestern Medical Center examined the use of guideline-directed medical therapies (GDMTs) for patients with newly diagnosed heart failure with reduced ejection fraction (HFrEF). The study found that GDMTs were underused, and there were sex disparities in the initiation and intensification of GDMT for HFrEF. Female patients had lower use of GDMTs compared to male patients, and overall use of optimal GDMT after HFrEF diagnosis was low. The study highlights the need for efforts to improve GDMT initiation and titration. [Extracted from the article]

A recent study conducted by investigators at New York Medical College examined the efficacy of various pharmacotherapies for heart failure with preserved ejection fraction (HFpEF). The study analyzed 22 randomized clinical trials involving over 30,000 participants and found that beta-blockers, mineralocorticoid receptor antagonist (MRA), angiotensin-converting enzyme inhibitors (ACE), angiotensin receptor blockers (ARB), angiotensin receptor-neprilysin inhibitor (ARNI), and sodium-glucose cotransporter-2 inhibitors (SGLT2i) did not significantly improve cardiovascular or all-cause mortality in HFpEF patients. However, the use of SGLT2i, ARNI, and MRA did reduce the risk of heart failure hospitalizations. The study concluded that further research is needed to determine the most effective treatment options for HFpEF. [Extracted from the article]

A report from the Royal Alexandra Hospital in Edmonton, Canada discusses the use of cardiac agents during neonatal cardiopulmonary resuscitation (CPR). Currently, epinephrine is the only recommended cardiac agent for neonatal resuscitation, but there is limited data on its optimal dosage and route of administration. The report suggests that vasopressin may be an alternative to epinephrine based on evidence from adult and pediatric studies, although there is a lack of neonatal data. The research concludes that more research is needed in this area. [Extracted from the article]

A recent study conducted at St Michael's Hospital in Toronto, Canada, has investigated the role of somatostatin-expressing neurons in opioid-induced respiratory depression. The study found that while somatostatin-expressing cells are involved in the regulation of breathing, they do not mediate the respiratory effects of opioids. Instead, other respiratory cell populations are likely responsible for these effects. The research provides valuable insights into the mechanisms of opioid-induced respiratory depression and highlights the need for further investigation in this area. [Extracted from the article]

Researchers from Bowdoin College in Brunswick, Maine have conducted a study on neuropeptidergic modulation in decapod crustacean cardiac and feeding systems. The study focuses on the stomatogastric nervous system and cardiac nervous system of these crustaceans, examining the specific signaling peptide sequences and their physiological effects. The research also explores how co-modulation by multiple peptides can generate surprising effects on circuit physiology and how modulation at different receptor sites can produce supra-additive effects. The study concludes by examining the protective role of modulation in making circuits robust to perturbations, such as changes in temperature. This research has been peer-reviewed and provides valuable insights into the field of neuropeptidergic modulation. [Extracted from the article]

A recent study conducted at the Lady Davis Institute for Medical Research in Montreal, Canada, has found that the activation of the purinergic receptor P2X7 (P2RX7) may contribute to hypertension and cardiovascular injury by promoting immune activation. The researchers used mice to investigate the effects of P2RX7 activation on blood pressure and cardiovascular function. They found that inhibiting P2RX7 reduced blood pressure elevation, preserved vascular function, and decreased immune cell infiltration, suggesting that P2RX7 may be a potential target for reducing blood pressure and associated vascular damage. The study was funded by various organizations, including the Canadian Institutes of Health Research and the National Institutes of Health. [Extracted from the article]

A report from researchers at Cedars Sinai Medical Center discusses the diverse biological functions of the renin-angiotensin system (RAS). While RAS is primarily known for its role in controlling blood pressure, it has also been found in unexpected locations in the body, such as the kidneys, brain, immune cells, and reproductive system. Understanding how RAS regulates these systems is important for gaining a better understanding of human physiology, mitigating the unintended consequences of RAS-inhibiting or activating drugs, and developing potential new therapies. The report provides an updated overview of the knowledge about local tissue RAS in various bodily systems, including their components, functions, and medical implications. [Extracted from the article]

Researchers at the University of Washington have conducted a study on chronic kidney disease (CKD) and the potential benefits of aldosterone synthase (AS) inhibition. The study investigated the efficacy and safety of a drug called BI 690517, with or without empagliflozin, in participants with CKD. The primary endpoint of the study was the change in urine albumin:creatinine ratio (UACR) at week 14. The study aimed to determine the appropriate dosage for further clinical development and assess the safety profile and potential kidney protection of BI 690517 in CKD patients already treated with a renin-angiotensin system inhibitor. [Extracted from the article]

A recent study conducted by AbbVie in Madison, New Jersey, examined the real-world persistence and costs among patients with chronic migraine who were treated with onabotulinumtoxinA (onabotA) or calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs). The study analyzed data from the IBM MarketScan Commercial and Medicare databases and included adults with chronic migraine who initiated treatment with either onabotA or CGRP mAbs. The findings showed that persistence rates to onabotA were higher compared to CGRP mAbs, and the study also identified common comorbid conditions among these patients, such as anxiety, depression, hypertension, and sleep disorders. This research provides valuable insights into the real-world use and costs of these migraine treatments. [Extracted from the article]

A new report from Houston Methodist Hospital discusses the management of pulmonary hypertension associated with valvular heart disease using an angiotensin-receptor neprilysin inhibitor (ARNI). The research highlights the potential role of ARNI in treating combined pre- and postcapillary pulmonary hypertension, independent of its effect on pulmonary capillary wedge pressure and cardiac output. The study concludes that future prospective trials are needed to further evaluate the use of ARNIs in the treatment of valvular heart disease-associated pulmonary hypertension. [Extracted from the article]

A recent study conducted at St. Paul's Hospital in Vancouver, Canada, explored the effects of Renin-Angiotensin-Aldosterone-System (RAAS) inhibitors on the progression of coronary atherosclerosis. The study involved a registry of patients without a history of coronary artery disease who underwent serial coronary CT angiography (CCTA). The results showed that the use of RAAS inhibitors did not significantly impact the progression of atherosclerotic plaques or various plaque components over a mean interval of 3.9 years. However, there was a significant decrease in the progression of non-calcified plaque in patients with a higher burden of baseline atherosclerosis. These findings should be considered hypothesis generating and further research is needed. [Extracted from the article]

Keywords: Aguascalientes; Mexico; North and Central America; Anxiety; Anxiety Disorders; Brain Ischemia; Central Nervous System Diseases and Conditions; Gonadotropin Releasing Hormones; Health and Medicine; Hypothalamic Hormones; Hypoxic-Ischemic Encephalopathy; Immunology; Intercellular Signaling Peptides and Proteins; Leuprolide; Membrane Proteins; Mental Health Diseases and Conditions; Nerve Tissue Proteins; Neuroinflammation; Neuropeptides; Peptide Hormones; Risk and Prevention; Tumor Necrosis Factors EN Aguascalientes Mexico North and Central America Anxiety Anxiety Disorders Brain Ischemia Central Nervous System Diseases and Conditions Gonadotropin Releasing Hormones Health and Medicine Hypothalamic Hormones Hypoxic-Ischemic Encephalopathy Immunology Intercellular Signaling Peptides and Proteins Leuprolide Membrane Proteins Mental Health Diseases and Conditions Nerve Tissue Proteins Neuroinflammation Neuropeptides Peptide Hormones Risk and Prevention Tumor Necrosis Factors 1011 1011 1 10/03/23 20231006 NES 231006 2023 OCT 6 (NewsRx) -- By a News Reporter-Staff News Editor at Genomics & Genetics Weekly -- New research on Central Nervous System Diseases and Conditions - Brain Ischemia is the subject of a report. Aguascalientes, Mexico, North and Central America, Anxiety, Anxiety Disorders, Brain Ischemia, Central Nervous System Diseases and Conditions, Gonadotropin Releasing Hormones, Health and Medicine, Hypoxic-Ischemic Encephalopathy, Hypothalamic Hormones, Immunology, Intercellular Signaling Peptides and Proteins, Membrane Proteins, Mental Health Diseases and Conditions, Nerve Tissue Proteins, Neuroinflammation, Neuropeptides, Peptide Hormones, Risk and Prevention, Tumor Necrosis Factors, Leuprolide. [Extracted from the article]

Montreal, Canada, North and Central America, Angiotensin II, Angiotensins, Autacoids, Biological Factors, Cardiovascular Agents, Cardiovascular Diseases and Conditions, Drugs and Therapies, Giapreza Therapy, Health and Medicine, Hypertension, Neuropeptides, Oligopeptides, Peptide Hormones, Peptide Proteins, Peptides, Proteins, Vasopressors Keywords: Montreal; Canada; North and Central America; Angiotensin II; Angiotensins; Autacoids; Biological Factors; Cardiovascular Agents; Cardiovascular Diseases and Conditions; Drugs and Therapies; Giapreza Therapy; Health and Medicine; Hypertension; Neuropeptides; Oligopeptides; Peptide Hormones; Peptide Proteins; Peptides; Proteins; Vasopressors EN Montreal Canada North and Central America Angiotensin II Angiotensins Autacoids Biological Factors Cardiovascular Agents Cardiovascular Diseases and Conditions Drugs and Therapies Giapreza Therapy Health and Medicine Hypertension Neuropeptides Oligopeptides Peptide Hormones Peptide Proteins Peptides Proteins Vasopressors 814 814 1 09/19/23 20230922 NES 230922 2023 SEP 18 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Investigators discuss new findings in Cardiovascular Diseases and Conditions - Hypertension. [Extracted from the article]

Toronto, Canada, North and Central America, Cells, Central Nervous System Agents, Drugs and Therapies, Fentanyl Therapy, G-Protein-Coupled Receptors, Health and Medicine, Membrane Proteins, Narcotic Analgesics, Nerve Tissue Proteins, Neurology, Neurons, Neuropeptide Receptors, Neuropeptides, Opiate Receptors, Opioid Receptors, Opioids, Pancreatic Hormones, Peptide Hormones, Peptide Proteins, Pharmaceuticals, Pituitary Hormone Release Inhibiting Hormones, Somatostatin, mu Receptors Keywords: Toronto; Canada; North and Central America; Cells; Central Nervous System Agents; Drugs and Therapies; Fentanyl Therapy; G-Protein-Coupled Receptors; Health and Medicine; Membrane Proteins; Narcotic Analgesics; Nerve Tissue Proteins; Neurology; Neurons; Neuropeptide Receptors; Neuropeptides; Opiate Receptors; Opioid Receptors; Opioids; Pancreatic Hormones; Peptide Hormones; Peptide Proteins; Pharmaceuticals; Pituitary Hormone Release Inhibiting Hormones; Somatostatin; mu Receptors EN Toronto Canada North and Central America Cells Central Nervous System Agents Drugs and Therapies Fentanyl Therapy G-Protein-Coupled Receptors Health and Medicine Membrane Proteins Narcotic Analgesics Nerve Tissue Proteins Neurology Neurons Neuropeptide Receptors Neuropeptides Opiate Receptors Opioid Receptors Opioids Pancreatic Hormones Peptide Hormones Peptide Proteins Pharmaceuticals Pituitary Hormone Release Inhibiting Hormones Somatostatin mu Receptors 846 846 1 08/28/23 20230901 NES 230901 2023 SEP 1 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- A new study on Opioids is now available. [Extracted from the article]

According to the news editors, the research concluded: "Electrical post-cardioversion recurrence in subjects with long-standing, persistent AF is associated with elevated levels of AngII and aldosterone." Keywords: Mexico City; Mexico; North and Central America; 11-Hydroxycorticosteroids; Adrenal Cortex Hormones; Aldosterone; Angiotensin II; Angiotensins; Atrial Fibrillation; Autacoids; Biological Factors; Biomarkers; Cardiac Arrhythmias; Diagnostics and Screening; Health and Medicine; Heart Disease; Heart Disorders and Diseases; Neuropeptides; Oligopeptides; Peptide Hormones; Peptide Proteins; Peptides; Proteins EN Mexico City Mexico North and Central America 11-Hydroxycorticosteroids Adrenal Cortex Hormones Aldosterone Angiotensin II Angiotensins Atrial Fibrillation Autacoids Biological Factors Biomarkers Cardiac Arrhythmias Diagnostics and Screening Health and Medicine Heart Disease Heart Disorders and Diseases Neuropeptides Oligopeptides Peptide Hormones Peptide Proteins Peptides Proteins 486 486 1 05/08/23 20230508 NES 230508 2023 MAY 8 (NewsRx) -- By a News Reporter-Staff News Editor at Cardiovascular Week -- Investigators publish new report on Heart Disorders and Diseases - Atrial Fibrillation. [Extracted from the article]

[Ga-68]Ga-TacBOMB2 showed comparable tumor uptake but superior tumor-to-background contrast ratios when compared to [Ga-68]Ga-AMBA. Keywords: Vancouver; Canada; North and Central America; Amphibian Venoms; Biological Factors; Biotechnology; Bombesin; Cancer; Gastroenterology; Health and Medicine; Neuropeptides; Oncology; Pancreas; Pancreas Research; Peptide Hormones; Peptide Proteins; Proteins EN Vancouver Canada North and Central America Amphibian Venoms Biological Factors Biotechnology Bombesin Cancer Gastroenterology Health and Medicine Neuropeptides Oncology Pancreas Pancreas Research Peptide Hormones Peptide Proteins Proteins 31 31 1 04/03/23 20230403 NES 230403 2023 APR 3 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Investigators publish new report on Peptide Proteins - Peptide Hormones. [Extracted from the article]

Seattle, State:Washington, United States, North and Central America, Antiestrogens, Antineoplastics, Drugs and Therapies, Eligard Therapy, Gender Health, Gender and Health, Gonadotropin Releasing Hormones, Health and Medicine, Hormones, Leuprolide, Hypothalamic Hormones, Leuprolide Therapy, Lupron Therapy, Nerve Tissue Proteins, Neuropeptides, Peptide Hormones, Pharmaceuticals, Sex Hormones, Women's Health, Leuprolide Acetate Keywords: Seattle; State:Washington; United States; North and Central America; Antiestrogens; Antineoplastics; Drugs and Therapies; Eligard Therapy; Gender Health; Gender and Health; Gonadotropin Releasing Hormones; Health and Medicine; Hormones; Hypothalamic Hormones; Leuprolide; Leuprolide Acetate; Leuprolide Therapy; Lupron Therapy; Nerve Tissue Proteins; Neuropeptides; Peptide Hormones; Pharmaceuticals; Sex Hormones; Women's Health EN Seattle State:Washington United States North and Central America Antiestrogens Antineoplastics Drugs and Therapies Eligard Therapy Gender Health Gender and Health Gonadotropin Releasing Hormones Health and Medicine Hormones Hypothalamic Hormones Leuprolide Leuprolide Acetate Leuprolide Therapy Lupron Therapy Nerve Tissue Proteins Neuropeptides Peptide Hormones Pharmaceuticals Sex Hormones Women's Health 2023 MAR 3 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Investigators publish new report on Drugs and Therapies - Antineoplastics. [Extracted from the article]

Keywords: Durham; State:North Carolina; United States; North and Central America; Calcitonin; Cancer; Endocrine Research; Endocrine Surgical Procedures; Genetics; Health and Medicine; Hormones; Medullary Thyroid Cancer; Neck Dissection; Neuropeptides; Oncology; Otorhinolaryngologic Surgical Procedures; Pathology; Peptide Hormones; Peptide Proteins; Proteins; Surgery; Thyroid Cancer; Thyroid Neoplasms; Thyroidectomy EN Durham State:North Carolina United States North and Central America Calcitonin Cancer Endocrine Research Endocrine Surgical Procedures Genetics Health and Medicine Hormones Medullary Thyroid Cancer Neck Dissection Neuropeptides Oncology Otorhinolaryngologic Surgical Procedures Pathology Peptide Hormones Peptide Proteins Proteins Surgery Thyroid Cancer Thyroid Neoplasms Thyroidectomy 2023 JAN 31 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Weekly -- Data detailed on Oncology - Medullary Thyroid Cancer have been presented. Pathology was benign (27.9%), papillary thyroid cancer alone (1.5%),C-cell hyperplasia (23.5%), and medullary thyroid cancer (47.1%; median tumor size = 3.0 mm). [Extracted from the article]